Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2025-12-24 @ 9:09 PM
NCT ID:
NCT03377504
Eligibility Criteria:
Inclusion Criteria:
* Adult individuals over 18 years of age
* CRPS type 1 diagnosis according to 2003 Budapest diagnostic criteria
* Patients who developed CRPS Type 1 due to traumatic causes (surgical procedures, fractures, immobilization)
* Patients who agree to participate in the study and sign the informed consent form
Exclusion Criteria:
* Patients with peripheral nerve injuries (those with a diagnosis of CRPS type 2 according to Budapest criteria)
* Patients with CRPS Type 1 after central nervous system injury (stroke)
* Patients in the acute and post-acute rehabilitation who have had primary or secondary tendon repair of the hand
* The presence of comorbid conditions (e.g. decompensated heart failure, chronic renal insufficiency, malignancy) that would impair the functioning of the person and the health-related quality of life
* The presence of comorbid disease affecting hand function (e.g. rheumatoid arthritis, psoriatic arthritis or other inflammatory diseases that cause hand involvement)
* Patients with acute deep venous thrombosis and arterial thrombosis of the upper extremity
* Patients with arterial / venous injury and / or undergoing arterial revascularization
* Patients with excessive alcohol and inappropriate opioid use
* Patients with untreated psychiatric problems (major depression, anxiety, schizophrenia, etc.)
* Patients with recurrent CRPS Type 1
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT03377504
Study Brief:
Protocol Section:
NCT03377504